Baricitinib*
-
API Product :
Baricitinib*
-
CEP :
-
-
WCC :
-
-
Therapeutic Use :
JAK Inhibitors
-
Originator :
Eli Lilly and Incyte Corporation
-
CAS No. :
1187594-09-7
-
Trade Name. :
Olumiant
-
Molecular Weight :
371.42 g/mol
-
Molecular Formula :
C16H17N7O2S
Application
Olumiant is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs. Olumiant may be used as monotherapy or in combination with methotrexate.
General Description
Baricitinib (trade name Olumiant) is a drug for the treatment of rheumatoid arthritis (RA), being developed by Incyte and Eli Lilly.[1] It acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2.[2] The drug is approved in Europe.